Comparison of Ocrelizumab and Rituximab over Two Years of Treatment for Multiple Sclerosis

被引：0
|
作者：
Vollmer, B. [1 ]
Nair, K. [2 ]
Sillau, S. [3 ]
Corboy, J. R. [3 ]
Alvarez, E. [3 ]
机构：
[1] Univ Colorado, Neurol, Denver, CO USA
[2] Univ Colorado, Pharm, Aurora, CO USA
[3] Univ Colorado, Neurol, Aurora, CO USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P159
引用
收藏
页码：92 / 93
页数：2
相关论文
共 50 条
  • [31] Two-year real-world experience with ocrelizumab in the treatment of patients with multiple sclerosis
    Vollmer, B.
    Ijadi, N.
    Declusin, A.
    Nair, K.
    Sillau, S.
    Corboy, J.
    Vollmer, T.
    Alvarez, E.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 595 - 596
  • [32] Ocrelizumab: A Review in Multiple Sclerosis
    Lamb, Yvette N.
    DRUGS, 2022, 82 (03) : 323 - 334
  • [33] Ocrelizumab: A Review in Multiple Sclerosis
    Yvette N. Lamb
    Drugs, 2022, 82 : 323 - 334
  • [34] Ocrelizumab: A Review in Multiple Sclerosis
    Yahiya Y. Syed
    CNS Drugs, 2018, 32 : 883 - 890
  • [35] Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis
    Gabelic, Tereza
    Barun, Barbara
    Adamec, Ivan
    Krbot Skoric, Magdalena
    Habek, Mario
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (11) : 4345 - 4362
  • [36] Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study
    Alcala, Carmen
    Quintanilla-Bordas, Carlos
    Gascon, Francisco
    Sempere, Angel Perez
    Navarro, Laura
    Carcelen-Gadea, Maria
    Landete, Lamberto
    Mallada, Javier
    Canizares, Emmanuel
    Belenguer, Antonio
    Carratala, Sara
    Dominguez, Jose Andres
    Perez-Miralles, Francisco Carlos
    Gil-Perotin, Sara
    Gasque, Raquel
    Cubas, Laura
    Castillo, Jessica
    Casanova, Bonaventura
    JOURNAL OF NEUROLOGY, 2022, 269 (07) : 3676 - 3681
  • [37] Characterization of mri activity following treatment with ocrelizumab for multiple sclerosis
    Bhattacharyya, S.
    Ali, A.
    Bakshi, R.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 382 - 383
  • [38] Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis
    Machlanska, Agnieszka
    Helbig, Grzegorz
    Chromik, Karolina
    Zapala, Magdalena
    Zwiernik, Bartosz
    Selmaj, Krzysztof
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (11) : 1803 - 1805
  • [39] Safety profile of Ocrelizumab for the treatment of multiple sclerosis: a systematic review
    Luzon, C.
    Ng, H. S.
    Tremlett, H.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 543 - 543
  • [40] Ocrelizumab treatment in multiple sclerosis patients with anti-HBc (+)
    Kubicka-Baczyk, K.
    Niedziela, N.
    Adamczyk, B.
    Nowak-Kiczmer, M.
    Adamczyk-Sowa, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 794 - 794
12345